FINWIRES · TerminalLIVE
FINWIRES

研究快訊:CFRA維持對波克夏海瑟威公司B類股票的「持有」評等。

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:我們維持對波克夏海瑟威公司12個月的目標價為520美元,基於我們2027年每股收益預期23.36美元(今日下修0.59美元)和2026年每股收益預期21.76美元(今日下修0.49美元),該股的本益比為過去三年的平均數2.3倍為本波克夏海瑟威2026年第一季每股收益預期為5.26美元,高於我們5.10美元的預期和5.05美元的普遍預期,預計營業收入將成長4.4%。我們維持2026年3%至7%的營業收入成長預期。稅前營業利潤翻了一番多,利潤率從5.6%擴大至13%,但GEICO的承保業績惡化,綜合比率從79.8%上升至87.3%。執行長格雷格·阿貝爾在其首次年度股東大會上重申了波克夏的收購策略和股票回購政策,但並未對預先設定的資本配置做出任何承諾。我們認為,以目前的股價計算,不含股息的股票估值合理。

Related Articles

Asia

Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers

Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said."Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.

$ASX:TLX
Asia

Huajin International Chairman, CEO Face Consumption Restriction Order

Huajin International (HKG:2738) said its chairman and chief executive were subject to a consumption restriction order due to the alleged nonpayment of amounts owed, according to a Hong Kong bourse filing Tuesday.The company's chairman Xu Songqing and chief executive Chen Chunniu have been subject to the consumption restriction order, effective Nov. 25.The case stems from the alleged non-payment of 130 million yuan by two of the company's units Jiangmen Huamu Metals and Jiangmen Huajin Metal Product, under a finance lease arrangement. As of April 30, 16.4 million yuan was still owed to the creditors.Both Xu and Chen have been negotiating with creditors to resolve the matter and the company expects to reach a settlement by the end of August.

$HKG:2738
Asia

Tata Chemicals' Consolidated Loss Widens in Fiscal Q4

Tata Chemicals' (NSE:TATACHEM, BOM:500770) consolidated attributable loss widened to 21.3 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 1.56 billion rupees a year ago.Loss per share grew to 83.68 rupees compared with a loss per share of 2.19 rupees a year earlier, the chemicals manufacturer said in a filing to the Indian bourses on Monday.Revenue from operations in fiscal Q4 declined to 34.4 billion rupees from 35.1 billion rupees a year ago. This was lower than the 34.8 billion rupees estimated by analysts polled by Visible Alpha.The company's board recommended a dividend of 11 rupees per share for the financial year ended March 31.

$BOM:500770$NSE:TATACHEM